Close Menu

Cleveland Clinic

News items for the in vitro diagnostics industry for the week of August 3, 2020.

The tests use a range of different specimens including self-collected nasal swabs, bronchoalveolar lavage, sputum, and nasopharyngeal washes.

Initiatives to develop commercial breath diagnostic systems reveal that developers are trying out lab-based mass spec systems and portable electronic noses.

The partners said that the first project will focus on the discovery of breath biomarkers for chronic liver diseases and liver-related cancers. 

The grant recipients will receive up to $5 million each and are led by scientists at institutions including Harvard Medical School and the Cleveland Clinic.

Both recent FDA draft guidance and a new research framework encourage the use of biomarker diagnostics to assess Alzheimer's before symptoms emerge.

Quest will have a broader relationship with Cleveland Clinic in diagnostic development, the companies say.

The firm believes the IsoPSA technology is superior to competitors, but clinicians argue that a lack of comparative studies could hamper adoption of all these tests.

As part of the acquisition, Quest has formalized an R&D agreement with Cleveland Clinic to commercialize emerging innovations.

Hospitals are increasingly recognizing the impact that improper lab test ordering can have on costs and patient care, doctors said.